Identification of a human blood biomarker of pharmacological 11β-hydroxysteroid dehydrogenase 1 inhibition.
11β-hydroxysteroid dehydrogenase
LC-MS
bile acid
biomarker
disease
glucocorticoid
inhibitor
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
23 Sep 2023
23 Sep 2023
Historique:
revised:
16
08
2023
received:
20
04
2023
accepted:
12
09
2023
pubmed:
23
9
2023
medline:
23
9
2023
entrez:
23
9
2023
Statut:
aheadofprint
Résumé
11β-Hydroxysteroid dehydrogenase-1 (11β-HSD1) catalyses the oxoreduction of cortisone to cortisol, amplifying levels of active glucocorticoids. It is a pharmaceutical target in metabolic disease and cognitive impairments. 11β-HSD1 also converts some 7oxo-steroids to their 7β-hydroxy forms. A recent study in mice described the ratio of tauroursodeoxycholic acid (TUDCA)/tauro-7oxolithocholic acid (T7oxoLCA) as a biomarker for decreased 11β-HSD1 activity. The present study evaluates the equivalent bile acid ratio of glycoursodeoxycholic acid (GUDCA)/glyco-7oxolithocholic acid (G7oxoLCA) as a biomarker for pharmacological 11β-HSD1 inhibition in humans and compares it with the currently applied urinary (5α-tetrahydrocortisol + tetrahydrocortisol)/tetrahydrocortisone ((5αTHF + THF)/THE) ratio. Bile acid profiles were analysed by ultra-HPLC tandem-MS in blood samples from two independent, double-blind placebo-controlled clinical studies of the orally administered selective 11β-HSD1 inhibitor AZD4017. The blood GUDCA/G7oxoLCA ratio was compared with the urinary tetrahydro-glucocorticoid ratio for ability to detect 11β-HSD1 inhibition. No significant alterations were observed in bile acid profiles following 11β-HSD1 inhibition by AZD4017, except for an increase of the secondary bile acid G7oxoLCA. The enzyme product/substrate ratio GUDCA/G7oxoLCA was found to be more reliable to detect 11β-HSD1 inhibition than the absolute G7oxoLCA concentration in both cohorts. Comparison of the blood GUDCA/G7oxoLCA ratio with the urinary (5αTHF + THF)/THE ratio revealed that both successfully detect 11β-HSD1 inhibition. 11β-HSD1 inhibition does not cause major alterations in bile acid homeostasis. The GUDCA/G7oxoLCA ratio represents the first blood biomarker of pharmacological 11β-HSD1 inhibition and may replace or complement the urinary (5αTHF + THF)/THE ratio biomarker.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
11β-Hydroxysteroid dehydrogenase-1 (11β-HSD1) catalyses the oxoreduction of cortisone to cortisol, amplifying levels of active glucocorticoids. It is a pharmaceutical target in metabolic disease and cognitive impairments. 11β-HSD1 also converts some 7oxo-steroids to their 7β-hydroxy forms. A recent study in mice described the ratio of tauroursodeoxycholic acid (TUDCA)/tauro-7oxolithocholic acid (T7oxoLCA) as a biomarker for decreased 11β-HSD1 activity. The present study evaluates the equivalent bile acid ratio of glycoursodeoxycholic acid (GUDCA)/glyco-7oxolithocholic acid (G7oxoLCA) as a biomarker for pharmacological 11β-HSD1 inhibition in humans and compares it with the currently applied urinary (5α-tetrahydrocortisol + tetrahydrocortisol)/tetrahydrocortisone ((5αTHF + THF)/THE) ratio.
EXPERIMENTAL APPROACH
METHODS
Bile acid profiles were analysed by ultra-HPLC tandem-MS in blood samples from two independent, double-blind placebo-controlled clinical studies of the orally administered selective 11β-HSD1 inhibitor AZD4017. The blood GUDCA/G7oxoLCA ratio was compared with the urinary tetrahydro-glucocorticoid ratio for ability to detect 11β-HSD1 inhibition.
KEY RESULTS
RESULTS
No significant alterations were observed in bile acid profiles following 11β-HSD1 inhibition by AZD4017, except for an increase of the secondary bile acid G7oxoLCA. The enzyme product/substrate ratio GUDCA/G7oxoLCA was found to be more reliable to detect 11β-HSD1 inhibition than the absolute G7oxoLCA concentration in both cohorts. Comparison of the blood GUDCA/G7oxoLCA ratio with the urinary (5αTHF + THF)/THE ratio revealed that both successfully detect 11β-HSD1 inhibition.
CONCLUSIONS AND IMPLICATIONS
CONCLUSIONS
11β-HSD1 inhibition does not cause major alterations in bile acid homeostasis. The GUDCA/G7oxoLCA ratio represents the first blood biomarker of pharmacological 11β-HSD1 inhibition and may replace or complement the urinary (5αTHF + THF)/THE ratio biomarker.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Swiss National Science Foundation
ID : 310030-214978
Pays : Switzerland
Organisme : Swiss National Science Foundation
ID : 31003A-179400
Pays : Switzerland
Informations de copyright
© 2023 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Alexander, S. P. H., Cidlowski, J. A., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Southan, C., Davies, J. A., Coons, L., Fuller, P. J., Korach, K. S., & Young, M. J. (2021). The concise guide to pharmacology 2021/22: Nuclear hormone receptors. British Journal of Pharmacology, 178, S246-S263. https://doi.org/10.1111/bph.15540
Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Southan, C., Davies, J. A., Annett, S., Boison, D., Burns, K. E., Dessauer, C., Gertsch, J., Helsby, N. A., Izzo, A. A., … Wong, S. S. (2021). The concise guide to pharmacology 2021/22: Enzymes. British Journal of Pharmacology, 178(S1), S313-S411. https://doi.org/10.1111/bph.15542
Anderson, A., & Walker, B. R. (2013). 11β-HSD1 inhibitors for the treatment of type 2 diabetes and cardiovascular disease. Drugs, 73(13), 1385-1393. https://doi.org/10.1007/s40265-013-0112-5
Beck, K. R., Inderbinen, S. G., Kanagaratnam, S., Kratschmar, D. V., Jetten, A. M., Yamaguchi, H., & Odermatt, A. (2019). 11β-Hydroxysteroid dehydrogenases control access of 7β,27-dihydroxycholesterol to retinoid-related orphan receptor γ. Journal of Lipid Research, 60(9), 1535-1546. https://doi.org/10.1194/jlr.M092908
Beck, K. R., Kanagaratnam, S., Kratschmar, D. V., Birk, J., Yamaguchi, H., Sailer, A. W., Seuwen, K., & Odermatt, A. (2019). Enzymatic interconversion of the oxysterols 7β,25-dihydroxycholesterol and 7-keto,25-hydroxycholesterol by 11β-hydroxysteroid dehydrogenase type 1 and 2. The Journal of Steroid Biochemistry and Molecular Biology, 190, 19-28. https://doi.org/10.1016/j.jsbmb.2019.03.011
Bhat, B. G., Hosea, N., Fanjul, A., Herrera, J., Chapman, J., Thalacker, F., Stewart, P. M., & Rejto, P. A. (2008). Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4′-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11β- hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys. Journal of Pharmacology and Experimental Therapeutics, 324(1), 299-305. https://doi.org/10.1124/jpet.107.128280
Bianzano, S., Heise, T., Jungnik, A., Schepers, C., Schölch, C., & Gräfe-Mody, U. (2021). Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1, in healthy male volunteers with overweight or obesity. Clinical Diabetes and Endocrinology, 7(1), 16. https://doi.org/10.1186/s40842-021-00130-x
Cain, D. W., & Cidlowski, J. A. (2017). Immune regulation by glucocorticoids. Nature Reviews Immunology, 17(4), 233-247. https://doi.org/10.1038/nri.2017.1
Chuanxin, Z., Shengzheng, W., Lei, D., Duoli, X., Jin, L., Fuzeng, R., Aiping, L., & Ge, Z. (2020). Progress in 11β-HSD1 inhibitors for the treatment of metabolic diseases: A comprehensive guide to their chemical structure diversity in drug development. European Journal of Medicinal Chemistry, 191, 112134. https://doi.org/10.1016/j.ejmech.2020.112134
Courtney, R., Stewart, P. M., Toh, M., Ndongo, M. N., Calle, R. A., & Hirshberg, B. (2008). Modulation of 11β-hydroxysteroid dehydrogenase (11βHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11αHSD1 inhibitor. Journal of Clinical Endocrinology and Metabolism, 93(2), 550-556. https://doi.org/10.1210/jc.2007-1912
Curtis, M. J., Alexander, S. P. H., Cirino, G., George, C. H., Kendall, D. A., Insel, P. A., Izzo, A. A., Ji, Y., Panettieri, R. A., Patel, H. H., Sobey, C. G., Stanford, S. C., Stanley, P., Stefanska, B., Stephens, G. J., Teixeira, M. M., Vergnolle, N., & Ahluwalia, A. (2022). Planning experiments: Updated guidance on experimental design and analysis and their reporting III. British Journal of Pharmacology, 179, 3907-3913. https://doi.org/10.1111/bph.15868
Feig, P. U., Shah, S., Hermanowski-Vosatka, A., Plotkin, D., Springer, M. S., Donahue, S., Thach, C., Klein, E. J., Lai, E., & Kaufman, K. D. (2011). Effects of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes, Obesity and Metabolism, 13(6), 498-504. https://doi.org/10.1111/j.1463-1326.2011.01375.x
Freude, S., Heise, T., Woerle, H.-J., Jungnik, A., Rauch, T., Hamilton, B., Schölch, C., Huang, F., & Graefe-Mody, U. (2016). Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: Liver and adipose tissue 11β-HSD1 inhibition after acute and multiple administrations over 2 weeks. Diabetes, Obesity and Metabolism, 18(5), 483-490. https://doi.org/10.1111/dom.12635
Gathercole, L. L., Lavery, G. G., Morgan, S. A., Cooper, M. S., Sinclair, A. J., Tomlinson, J. W., & Stewart, P. M. (2013). 11β-Hydroxysteroid dehydrogenase 1: Translational and therapeutic aspects. Endocrine Reviews, 34(4), 525-555. https://doi.org/10.1210/er.2012-1050
Gómez, C., Stücheli, S., Kratschmar, D. V., Bouitbir, J., & Odermatt, A. (2020). Development and validation of a highly sensitive LC-MS/MS method for the analysis of bile acids in serum, plasma, and liver tissue samples. Metabolites, 10(7), 282. https://doi.org/10.3390/metabo10070282
Gregory, S., Hill, D., Grey, B., Ketelbey, W., Miller, T., Muniz-Terrera, G., & Ritchie, C. W. (2020). 11β-Hydroxysteroid dehydrogenase type 1 inhibitor use in human disease-A systematic review and narrative synthesis. Metabolism, Clinical and Experimental, 108, 154246. https://doi.org/10.1016/j.metabol.2020.154246
Hardy, R. S., Botfield, H., Markey, K., Mitchell, J. L., Alimajstorovic, Z., Westgate, C. S. J. J., Sagmeister, M., Fairclough, R. J., Ottridge, R. S., Yiangou, A., Storbeck, K.-H. H. H., Taylor, A. E., Gilligan, L. C., Arlt, W., Stewart, P. M., Tomlinson, J. W., Mollan, S. P., Lavery, G. G., & Sinclair, A. J. (2021). 11βHSD1 inhibition with AZD4017 improves lipid profiles and lean muscle mass in idiopathic intracranial hypertension. Journal of Clinical Endocrinology and Metabolism, 106(1), 174-187. https://doi.org/10.1210/clinem/dgaa766
Heise, T., Morrow, L., Hompesch, M., Häring, H.-U., Kapitza, C., Abt, M., Ramsauer, M., Magnone, M.-C., & Fuerst-Recktenwald, S. (2014). Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 16(11), 1070-1077. https://doi.org/10.1111/dom.12317
Hult, M., Elleby, B., Shafqat, N., Svensson, S., Rane, A., Jörnvall, H., Abrahmsen, L., & Oppermann, U. (2004). Human and rodent type 1 11b-hydroxysteroid dehydrogenases are 7b-hydroxycholesterol dehydrogenases involved in oxysterol metabolism. Cellular and Molecular Life Sciences: CMLS, 61(7-8), 992-999. https://doi.org/10.1007/s00018-003-3476-y
Jamieson, A., Wallace, A. M., Andrew, R., Nunez, B. S., Walker, B. R., Fraser, R., White, P. C., & Connell, J. M. C. (1999). Apparent cortisone reductase deficiency: A functional defect in 11β-hydroxysteroid dehydrogenase type 1. Journal of Clinical Endocrinology and Metabolism, 84(10), 3570-3574. https://doi.org/10.1210/jcem.84.10.6031
Johnson, J. S., Opiyo, M. N., Thomson, M., Gharbi, K., Seckl, J. R., Heger, A., & Chapman, K. E. (2017). 11β-hydroxysteroid dehydrogenase-1 deficiency alters the gut microbiome response to Western diet. Journal of Endocrinology, 232(2), 273-283. https://doi.org/10.1530/JOE-16-0578
Markey, K., Mitchell, J., Botfield, H., Ottridge, R. S., Matthews, T., Krishnan, A., Woolley, R., Westgate, C., Yiangou, A., Alimajstorovic, Z., Shah, P., Rick, C., Ives, N., Taylor, A. E., Gilligan, L. C., Jenkinson, C., Arlt, W., Scotton, W., Fairclough, R. J., … Sinclair, A. J. (2020). 11β-Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: A double-blind randomized controlled trial. Brain Communications, 2(1), 1, fcz050-12. https://doi.org/10.1093/braincomms/fcz050
Markey, K. A., Ottridge, R., Mitchell, J. L., Rick, C., Woolley, R., Ives, N., Nightingale, P., & Sinclair, A. J. (2017). Assessing the efficacy and safety of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor (AZD4017) in the idiopathic intracranial hypertension drug trial, IIH:DT: Clinical methods and design for a phase II randomized controlled trial. JMIR Research Protocols, 6(9), e181. https://doi.org/10.2196/resprot.7806
Mitić, T., Shave, S., Semjonous, N., McNae, I., Cobice, D. F., Lavery, G. G., Webster, S. P., Hadoke, P. W. F., Walker, B. R., & Andrew, R. (2013). 11β-Hydroxysteroid dehydrogenase type 1 contributes to the balance between 7-keto- and 7-hydroxy-oxysterols in vivo. Biochemical Pharmacology, 86(1), 146-153. https://doi.org/10.1016/j.bcp.2013.02.002
Odermatt, A., Da Cunha, T., Penno, C. A., Chandsawangbhuwana, C., Reichert, C., Wolf, A., Dong, M., & Baker, M. E. (2011). Hepatic reduction of the secondary bile acid 7-oxolithocholic acid is mediated by 11β-hydroxysteroid dehydrogenase 1. Biochemical Journal, 436(3), 621-629. https://doi.org/10.1042/BJ20110022
Odermatt, A., Dick, B., Arnold, P., Zaehner, T., Plueschke, V., Deregibus, M. N., Repetto, H., Frey, B. M., Frey, F. J., & Ferrari, P. (2001). A mutation in the cofactor-binding domain of 11β-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension. Journal of Clinical Endocrinology and Metabolism, 86(3), 1247-1252. https://doi.org/10.1210/jcem.86.3.7334
Odermatt, A., & Klusonova, P. (2015). 11β-Hydroxysteroid dehydrogenase 1: Regeneration of active glucocorticoids is only part of the story. Journal of Steroid Biochemistry and Molecular Biology, 151, 85-92. https://doi.org/10.1016/j.jsbmb.2014.08.011
Odermatt, A., & Kratschmar, D. V. (2012). Tissue-specific modulation of mineralocorticoid receptor function by 11β-hydroxysteroid dehydrogenases: An overview. Molecular and Cellular Endocrinology, 350(2), 168-186. https://doi.org/10.1016/j.mce.2011.07.020
Othonos, N., Pofi, R., Arvaniti, A., White, S., Bonaventura, I., Nikolaou, N., Moolla, A., Marjot, T., Stimson, R. H., van Beek, A. P., van Faassen, M., Isidori, A. M., Bateman, E., Sadler, R., Karpe, F., Stewart, P. M., Webster, C., Duffy, J., Eastell, R., … Tomlinson, J. W. (2023). 11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomized double-blind placebo-controlled trial. Nature Communications, 14(1), 1025. https://doi.org/10.1038/s41467-023-36541-w
Palermo, M., Shackleton, C. H. L., Mantero, F., & Stewart, P. M. (1996). Urinary free cortisone and the assessment of 11β-hydroxysteroid dehydrogenase activity in man. Clinical Endocrinology, 45(5), 605-611. https://doi.org/10.1046/j.1365-2265.1996.00853.x
Penno, C. A., Morgan, S. A., Rose, A. J., Herzig, S., Lavery, G. G., & Odermatt, A. (2014). 11β-Hydroxysteroid dehydrogenase-1 is involved in bile acid homeostasis by modulating fatty acid transport protein-5 in the liver of mice. Molecular Metabolism, 3(5), 554-564. https://doi.org/10.1016/j.molmet.2014.04.008
Penno, C. A., Morgan, S. A., Vuorinen, A., Schuster, D., Lavery, G. G., & Odermatt, A. (2013). Impaired oxidoreduction by 11β-hydroxysteroid dehydrogenase 1 results in the accumulation of 7-oxolithocholic acid. Journal of Lipid Research, 54(10), 2874-2883. https://doi.org/10.1194/jlr.M042499
Reichardt, S. D., Amouret, A., Muzzi, C., Vettorazzi, S., Tuckermann, J. P., Lühder, F., & Reichardt, H. M. (2021). The role of glucocorticoids in inflammatory diseases. Cell, 10(11), 2921. https://doi.org/10.3390/cells10112921
Russell, D. W., & Setchell, K. D. R. (1992). Bile acid biosynthesis. Biochemistry, 31(20), 4737-4749. https://doi.org/10.1021/bi00135a001
Sagmeister, M. S., Taylor, A. E., Fenton, A., Wall, N. A., Chanouzas, D., Nightingale, P. G., Ferro, C. J., Arlt, W., Cockwell, P., Hardy, R. S., & Harper, L. (2019). Glucocorticoid activation by 11β-hydroxysteroid dehydrogenase enzymes in relation to inflammation and glycaemic control in chronic kidney disease: A cross-sectional study. Clinical Endocrinology, 90, 241-249. https://doi.org/10.1111/cen.13889
Schwab, D., Sturm, C., Portron, A., Fuerst-Recktenwald, S., Hainzl, D., Jordan, P., Stewart, W. C., Tepedino, M. E., & DuBiner, H. (2017). Oral administration of the 11β-hydroxysteroid-dehydrogenase type 1 inhibitor RO5093151 to patients with glaucoma: An adaptive, randomised, placebo-controlled clinical study. BMJ Open Ophthalmology, 1(1), e000063. https://doi.org/10.1136/bmjophth-2016-000063
Schweizer, R. A. S., Zürcher, M., Balazs, Z., Dick, B., & Odermatt, A. (2004). Rapid hepatic metabolism of 7-Ketocholesterol by 11β-hydroxysteroid dehydrogenase type 1. Journal of Biological Chemistry, 279(18), 18415-18424. https://doi.org/10.1074/jbc.M313615200
Scott, J. S., Bowker, S. S., DeSchoolmeester, J., Gerhardt, S., Hargreaves, D., Kilgour, E., Lloyd, A., Mayers, R. M., McCoull, W., Newcombe, N. J., Ogg, D., Packer, M. J., Rees, A., Revill, J., Schofield, P., Selmi, N., Swales, J. G., & Whittamore, P. R. O. (2012). Discovery of a potent, selective, and orally bioavailable acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor: Discovery of 2-[(3 S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid (AZD4017). Journal of Medicinal Chemistry, 55(12), 5951-5964. https://doi.org/10.1021/jm300592r
Scott, J. S., Goldberg, F. W., & Turnbull, A. V. (2014). Medicinal chemistry of inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). Journal of Medicinal Chemistry, 57(11), 4466-4486. https://doi.org/10.1021/jm4014746
Shackleton, C. H. L. (1993). Mass spectrometry in the diagnosis of steroid-related disorders and in hypertension research. The Journal of Steroid Biochemistry and Molecular Biology, 45(1-3), 127-140. https://doi.org/10.1016/0960-0760(93)90132-G
Shah, S., Hermanowski-Vosatka, A., Gibson, K., Ruck, R. A., Jia, G., Zhang, J., Hwang, P. M. T., Ryan, N. W., Langdon, R. B., & Feig, P. U. (2011). Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. Journal of the American Society of Hypertension, 5(3), 166-176. https://doi.org/10.1016/j.jash.2011.01.009
Stefan, N., Ramsauer, M., Jordan, P., Nowotny, B., Kantartzis, K., Machann, J., Hwang, J.-H. H., Nowotny, P., Kahl, S., Harreiter, J., Hornemann, S., Sanyal, A. J., Stewart, P. M., Pfeiffer, A. F., Kautzky-Willer, A., Roden, M., Häring, H.-U. U., Fürst-Recktenwald, S., Pfeiff, A. F., & Kautzky-Willer, A. (2014). Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: A multicentre, randomised, double-blind, placebo-controlled trial. The Lancet Diabetes & Endocrinology, 2(5), 406-416. https://doi.org/10.1016/S2213-8587(13)70170-0
Tomlinson, J. W., & Stewart, P. M. (2001). Cortisol metabolism and the role of 11β-hydroxysteroid dehydrogenase. Best Practice & Research. Clinical Endocrinology & Metabolism, 15(1), 61-78. https://doi.org/10.1053/beem.2000.0119
Webster, S. P., McBride, A., Binnie, M., Sooy, K., Seckl, J. R., Andrew, R., Pallin, T. D., Hunt, H. J., Perrior, T. R., Ruffles, V. S., Ketelbey, J. W., Boyd, A., & Walker, B. R. (2017). Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™). British Journal of Pharmacology, 174(5), 396-408. https://doi.org/10.1111/bph.13699
Weingartner, M., Stücheli, S., Kratschmar, D. V., Birk, J., Klusonova, P., Chapman, K. E., Lavery, G. G., & Odermatt, A. (2021). The ratio of ursodeoxycholyltaurine to 7-oxolithocholyltaurine serves as a biomarker of decreased 11β-hydroxysteroid dehydrogenase 1 activity in mouse. British Journal of Pharmacology, 178, 3309-3326. https://doi.org/10.1111/bph.15367